Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension
##plugins.themes.academic_pro.article.main##
Abstract
Hypertension is an important risk factor for cardiovascular and renal disease. It’s early detection and control is critically important as it is an important attributable cause of stroke, coronary artery disease, heart failure, atrial fibrillation and ESRD. Recent data indicates increasing prevalence of hypertension amongst various populations. This reflects the importance of having a variety of treatment options for the management of this condition. Angiotensin receptor blockers are highly effective at reducing blood pressure, have excellent tolerability and renoprotective properties, hence they remain a useful choice in the management of hypertension. Azilsartan medoxomil has recently been approved by the FDA for the oral treatment of hypertension making it the eighth Angiotensin receptor blocker to be approved for this indication.
##plugins.themes.academic_pro.article.details##
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
Sood, M., Bajaj, J. K., & Bajaj, J. K. (2013). Azilsartan Medoxomil: Angiotensin Receptor Blocker in the Treatment of Hypertension. International Journal of Medical and Dental Sciences, 100–103. https://doi.org/10.18311/ijmds/2013/19830
References
- Carretero OA, Oparil S. Essential Hypertension: Part I: Definition and Etiology. Circulation 2000; 101:329-335.
- Joshi SR, Saboo B, Vadivale M, Dani SI, Mithal A, Kaul U, et al. On Behalf Of The Site Investigators JJ. Prevalence of Diagnosed and Undiagnosed Diabetes and Hypertension in India-Results from the Screening India's Twin Epidemic (SITE) Study. Diabetes Technol Ther 2012 Jan; 14(1):8-15.
- Healey JS, Connolly SJ. Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003; 91:9G–14G.
- Chrysant SG, Chrysant GS and Desai A. Current status of angiotensin receptor blockers for the treatment of cardiovascular diseases: focus on telmisartan. Journal of Human Hypertension 2005; 19:173–183.
- Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs 2008; 68(9):1207-25.
- Azilsartan medoxomil (Edarbi) the eighth ARB. Med Lett Drugs Ther 2011 May 16; 53(1364):39-40.
- Vasiliou S. Azilsartan medoxomil for the treatment of hypertension. Drugs Today (Barc) 2011 Sep; 47(9):647-51.
- Drug information. FDA approved drugs 2011. Center watch. Downloaded on December 16, 2011.
- Edarbi (Azilsartan Medoxomil) drug information. Downloaded from www.rxlist.com. On 14.01.2012
- Zaiken K, Cheng JW. Azilsartan medoxomil: a new Angiotensin receptor blocker. Clin Ther 2011 Nov;
- (11):1577-89.
- Baker WL, White WB. Azilsartan Medoxomil: A New Angiotensin II Receptor Antagonist for Treatment of Hypertension (December). Ann Pharmacother 2011 Nov 24.
- Bakris GL, Sica D, Weber M, White WB, Roberts A, Perez A, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011 Feb; 13(2):81-8.
- Sica D, White WB, Weber MA, Bakris GL, Perez A, Cao C, et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011 Jul; 13(7):467-72.
- Kajiya T, Ho C, Wang J, Vilardi R, Kurtz TW. Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker. J Hypertens 2011 Dec; 29(12):2476-83.